Figure 5
Figure 5. Hemoglobin concentrations, neutrophil counts, and platelet counts. (A) Hemoglobin concentrations (g/L). (B) Neutrophil counts (109/L). (C) Platelet counts (109/L) for cohort D over a 40-week time period. Cohort D was the maximal dose cohort in this protocol, with each patient receiving a maximal cumulative whole-body dose greater than 125 cGy in 2 fractions of 131I-rituximab.

Hemoglobin concentrations, neutrophil counts, and platelet counts. (A) Hemoglobin concentrations (g/L). (B) Neutrophil counts (109/L). (C) Platelet counts (109/L) for cohort D over a 40-week time period. Cohort D was the maximal dose cohort in this protocol, with each patient receiving a maximal cumulative whole-body dose greater than 125 cGy in 2 fractions of 131I-rituximab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal